Advisor profile illustration
← 상담사로 돌아가기

Ahmed Hassan

Rebirthealth 인증 완료
Conventional medicine

Practicing in Cairo, Egypt · Arabic, English, French

새 작업 수락 중

소개

I am a pulmonologist with 18 years of clinical experience specializing in chronic respiratory diseases and critical care medicine. My career has been dedicated to helping patients with complex lung conditions navigate their diagnoses and find effective treatment pathways. After completing my medical degree at Cairo University and my fellowship in Pulmonary and Critical Care Medicine at Ain Shams University Hospital, I developed particular expertise in managing COPD, bronchial asthma, interstitial lung diseases, and pulmonary hypertension—conditions that often require nuanced, long-term management strategies. My practice is built on the principle that respiratory health is foundational to quality of life. I have managed thousands of patients with chronic obstructive pulmonary disease across all stages, from early intervention through advanced disease management including non-invasive ventilation support. I hold certification in interventional pulmonology, which allows me to offer expertise in advanced diagnostic and therapeutic bronchoscopic procedures. I stay actively engaged with the latest developments in respiratory medicine, including biologic therapies for severe asthma and antifibrotic treatments for interstitial lung disease. I believe that effective pulmonary care requires clear communication and patient education. Many respiratory conditions are lifelong companions, and my role is to empower patients with the understanding they need to manage their conditions proactively. Through Rebirthealth, I offer consultative guidance on diagnosis interpretation, treatment optimization, medication management, and lifestyle modifications that can significantly improve respiratory outcomes. I am particularly passionate about helping patients who feel they have exhausted conventional options to explore emerging therapies and clinical trial opportunities.

자격 증명

Doctor of Medicine (MD)

Cairo University Faculty of Medicine, 2006

✓ 인증됨

Fellowship in Pulmonary & Critical Care Medicine

Ain Shams University Hospital, 2010

✓ 인증됨

Certification in Interventional Pulmonology

Egyptian Board of Pulmonary Medicine, 2013–2028

✓ 인증됨


사례 증거

사례 · 익명화됨

I consulted with a 58-year-old man with severe COPD who was experiencing frequent exacerbations despite maximal inhaler therapy. After reviewing his regimen, I recommended adjustments including adding roflumilast and optimizing his inhaler technique, which reduced his exacerbation frequency by over 60% within four months. Verified by Rebirthealth.


사례 · 익명화됨

I advised a 35-year-old woman with treatment-resistant asthma who had been hospitalized three times in one year. My assessment identified her as a candidate for biologic therapy targeting IL-5, and after coordinating with her local team to initiate treatment, she remained hospitalization-free for over 14 months. Verified by Rebirthealth.


사례 · 익명화됨

I provided a second opinion for a 62-year-old patient diagnosed with idiopathic pulmonary fibrosis who was uncertain about starting antifibrotic medication. I explained the evidence for nintedanib, addressed his concerns about side effects, and helped him make an informed decision to begin treatment early, which has helped stabilize his lung function. Verified by Rebirthealth.


플랫폼 이력

완료된 작업26 작업평균 응답 시간~14 첫 제안까지 남은 시간평균 동료 점수9.1 / 10사용 언어Arabic, English, French가입함January 2024

클라이언트 피드백

23 of 26 clients marked this advisor's work as "what they hoped for"

Dr. Hassan explained my COPD management options with exceptional clarity. He identified gaps in my treatment that my local doctors had missed, and his recommendations made a real difference in my daily breathing.

— Client, Respiratory Care, Q3 2024

His knowledge of the latest asthma biologics was invaluable. He helped me understand which treatment pathway was right for my specific type of asthma and guided me through the entire process with patience.

— Client, Treatment Guidance, Q1 2025